General MedicationsSUBCUTANEOUSStandard
YUVIWEL
NAVEPEGRITIDE
Standard Dose
5.5MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview YUVIWEL is listed in Drugs@FDA under application 219164 (NDA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient NAVEPEGRITIDE Form and strength POWDER;SUBCUTANEOUS - 5.5MG/VIAL Sponsor ASCENDIS Submission history Latest submission status date: 2026-02-27 00:00:00.
Structured Monograph
Clinical summary
Approval overview YUVIWEL is listed in Drugs@FDA under application 219164 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient NAVEPEGRITIDE Form and strength POWDER;SUBCUTANEOUS - 5.5MG/VIAL Sponsor ASCENDIS Submission history Latest submission status date: 2026-02-27 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.